U-NEURON Biomedical Presented UA002 Ahead of BioJapan, Impressing International Stakeholders
Regenerative medicine company U-NEURON Biomedical presented its proprietary amniotic fluid stem cell drug candidate UA002 during the Link-J roadshow session prior to BioJapan on October 7. BioJapan is Asia’s flagship medical exhibition, serving as an ideal platform for regenerative medicine. The Link-J Global Life Science Session brought together participants from over 10 countries across the Americas, Japan, Europe, Asia, and Australia. Led by the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) of the Ministry of Economic Affairs, the delegation introduced top-performing Taiwanese biomedical companies during the international roadshow. U-NEURON Chief Operating Officer Shin-Yi Chuang presented UA002, a novel candidate for sexual dysfunction with significant potential for neural regeneration. In clinical evaluations, UA002 demonstrated exceptional efficacy for erectile dysfunction non-responsive to oral medications, with multiple research papers published in authoritative international journals. The presentation successfully captured global attention in Japan, a pioneer in regenerative medicine.